V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220017989 | 220009212 | 1.76 | 97 | null | 2017-08-27 | 2017-10-15 | Ipilimumab | N | N | 220034678 | RAVVA TRIAL |
| 220017990 | 220009216 | 1.64 | 70.6 | Palliative (P) | null | 2017-05-27 | FIGARO TRIAL | 2 | N | 220034686 | TRASTUZUMAB |
| 220017991 | 220009218 | 1.6 | 60.6 | Curative (C) | 2016-03-26 | 2016-03-30 | CAPECITABINE + OXALIPLATIN | 2 | N | 220034690 | FCR |
| 220017992 | 220014906 | 1.63 | 62 | Curative (C) | 2011-05-27 | 2013-07-25 | CLADRIBINE | 2 | N | 220034697 | DABRAFENIB + TRAMETINIB |
| 220017993 | 220009226 | 1.73 | 63.7 | null | 2014-10-01 | 2014-10-07 | BUSULFAN + CYCLO | 02 | N | 220034714 | MACE |
| 220017994 | 220009227 | 1.62 | 78.8 | Curative (C) | 2014-12-16 | 2015-02-08 | Ipilimumab | 2 | N | 220034715 | PEMBROLIZUMAB |
| 220017996 | 220009231 | null | null | Curative (C) | 2016-11-08 | 2016-11-09 | Alemtuzumab+Busulfan+CyclophosphMUD | 99 | N | 220034742 | MYELOMA XI TRIAL |
| 220017997 | 220009233 | 1.84 | 9.7 | null | 2013-11-20 | 2014-07-04 | CHOP R - 21 days | N | N | 220034750 | MPT |
| 220017998 | 220014913 | 0 | 95.4 | Curative (C) | 2018-03-01 | 2018-03-01 | MITOXANTRONE + TRETINOIN | 1 | N | 220034781 | CETUXIMAB + IRINOTECAN + MDG |
| 220017999 | 220009238 | null | 85 | Curative (C) | 2014-11-10 | 2014-11-10 | Arsenic Triox + Tretinoin Ind W1-4 | 01 | null | 220034796 | ARSENIC TRIOXIDE |
| 220018000 | 220009241 | 1.4 | 47 | Curative (C) | 2018-01-09 | 2018-01-11 | Capecitabine | 01 | N | 220034798 | PEMBROLIZUMAB |
| 220018001 | 220009241 | 1.55 | 8.9 | Curative (C) | 2013-12-10 | 2013-12-16 | IPILIMUMAB + NIVOLUMAB | 01 | N | 220034798 | LI-1 TRIAL |
| 220018002 | 220014915 | 1.95 | 41.2 | Palliative (P) | null | 2015-09-03 | CLOFARABINE + DAUNORUBICIN | null | N | 220034800 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220018003 | 220009244 | null | 78.4 | Curative (C) | 2015-03-05 | 2015-03-05 | CLOFARABINE + CYCLO + CYTARABINE + ETOP | N | N | 220034800 | TRASTUZUMAB |
| 220018004 | 220014917 | 1.72 | 75.6 | Curative (C) | 2014-07-17 | 2014-09-05 | Cisplatin 7 day | 02 | N | 220034818 | TRASTUZUMAB |
| 220018005 | 220009248 | null | 73 | Curative (C) | 2019-01-14 | 2019-01-18 | Cyclophosphamide+Etopophos HD | 02 | null | 220034830 | METHOTREXATE HIGH DOSE |
| 220018006 | 220009248 | 1.4 | 70.1 | Curative (C) | 2016-01-22 | 2016-02-28 | Arsenic Triox + Tretinoin Ind W1-4 | null | null | 220034830 | TEMOZOLOMIDE |
| 220018007 | 220009251 | 1.67 | 70.5 | Curative (C) | 2016-11-19 | 2016-12-09 | Cetuximab 7 day (>Cycle 2) | N | N | 220034845 | MIDAC |
| 220018008 | 220009254 | 1.65 | 9.4 | null | 2016-12-11 | 2016-12-12 | Alemtuzumab+Busulfan+CyclophosphMUD | N | null | 220034881 | CYTARABINE IT + METHOTREXATE |
| 220018009 | 220009255 | 1.57 | 60 | Curative (C) | 2017-09-08 | 2017-10-08 | ALL UKALL2011 TRIAL | 02 | N | 220034891 | ARSENIC TRIOXIDE + ATRA |
| 220018010 | 220009257 | 1.75 | 90 | Curative (C) | 2015-09-22 | 2015-09-22 | MidAC | 01 | N | 220034893 | ETOPOSIDE |
| 220018011 | 220018146 | 1.69 | null | Curative (C) | 2013-10-15 | 2013-10-21 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE + MELPHALAN | N | N | 220034910 | CISPLATIN + RT |
| 220018012 | 220009260 | 1.76 | 63 | Curative (C) | 2013-11-03 | 2014-04-07 | Alemtuzumab + Cyclophos TBI Allo | N | Y | 220034927 | CYTARABINE + FLUDARABINE |
| 220018013 | 220009262 | 1.65 | 89 | Curative (C) | 2016-10-19 | 2016-11-15 | INTERFERON | 02 | N | 220034933 | CAPECITABINE + CARBOPLATIN |
| 220018014 | 220009265 | 1.65 | 65.8 | Curative (C) | 2014-11-27 | 2014-12-10 | Cyclophos + Dex + Lenalidomide | N | N | 220034935 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018015 | 220009268 | 1.62 | 80.7 | Curative (C) | 2017-07-03 | 2017-07-03 | DABRAFENIB | N | N | 220034947 | VINCRISTINE |
| 220018016 | 220021010 | 1.76 | 76 | Disease modification (D) | 2013-02-21 | 2013-06-09 | Capecitabine | N | N | 220035027 | ARSENIC TRIOXIDE |
| 220018017 | 220018149 | 1.7 | 76 | Curative (C) | 2017-06-02 | 2017-06-10 | GEMCITABINE | 01 | N | 220035062 | BUSULPHAN |
| 220018018 | 220009275 | 1.83 | 67.5 | Curative (C) | 2014-06-16 | 2014-07-28 | MidAC | 2 | N | 220035062 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018019 | 220009277 | null | null | Curative (C) | 2016-07-24 | 2016-07-28 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | null | N | 220035065 | MYELOMA XI TRIAL |
| 220018021 | 220009284 | 1.7 | 11.1 | Curative (C) | 2017-09-15 | 2017-10-27 | CLOFARABINE + DAUNORUBICIN | N | N | 220035089 | UKALL 2003 |
| 220018025 | 220009294 | 1.56 | null | Curative (C) | 2012-10-22 | 2014-03-04 | LENALIDOMIDE | N | N | 220035110 | PEMBROLIZUMAB |
| 220018026 | 220018155 | 1.56 | 78.3 | Curative (C) | null | 2014-12-12 | Cytarabine+Methotrexate Intrathecal | N | N | 220035113 | CYTARABINE + MITOXANTRONE |
| 220018028 | 220014940 | null | 82 | Curative (C) | 2016-05-10 | 2016-05-18 | IBRUTINIB | null | null | 220035134 | METHOTREXATE + PEGASPARGASE |
| 220018029 | 220009300 | 1.73 | 82 | null | 2014-10-03 | 2017-02-25 | Cisplatin + Radiotherapy | N | N | 220035146 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 220018030 | 220009304 | 1.68 | 72.5 | Curative (C) | 2017-10-07 | 2017-10-07 | PEMBROLIZUMAB | Y | null | 220035152 | UKALL60+ |
| 220018031 | 220009306 | null | 74.4 | Curative (C) | 2016-09-23 | 2016-09-27 | Enzalutamide | N | null | 220035158 | INTERFERON |
| 220018032 | 220009308 | 1.64 | 125 | null | 2017-07-09 | 2017-07-10 | AXITINIB | N | N | 220035169 | PEMETREXED |
| 220018033 | 220009311 | null | null | Curative (C) | 2016-01-13 | 2016-01-15 | Alemtuzumab+Busulfan+CyclophosphMUD | 99 | null | 220035188 | SORAFENIB |
| 220018034 | 220009312 | 1.81 | 64.7 | Curative (C) | 2017-09-22 | 2017-09-25 | Arsenic Trioxide (consolidation) | N | N | 220035189 | RAVVA TRIAL |
| 220018035 | 220009317 | 1.64 | 62.2 | Curative (C) | 2015-08-29 | 2017-01-29 | FIGARO TRIAL | N | N | 220035190 | ARSENIC TRIOXIDE + ATRA |
| 220018037 | 220009321 | 1.73 | 67.1 | Curative (C) | 2015-06-13 | 2015-06-13 | ALL UKALL2011 Std BFM Cons B | Y | N | 220035200 | FIGARO TRIAL |
| 220018038 | 220009323 | null | null | Curative (C) | 2015-06-01 | 2015-06-18 | BUSULFAN | N | N | 220035212 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220018039 | 220018158 | 1.66 | -1 | Curative (C) | 2014-04-04 | 2014-04-08 | FLUDARABINE | N | null | 220035219 | FLUDARABINE |
| 220018040 | 220009326 | 1.79 | 83.7 | Curative (C) | 2018-01-14 | 2018-08-29 | BUSULFAN + FLUDARABINE + METHOTREXATE | 01 | N | 220035229 | GCLAC |
| 220018041 | 220009329 | null | 47 | Curative (C) | 2016-09-02 | 2017-08-09 | PAC-E | 01 | N | 220035232 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220018042 | 220009330 | null | 90 | Curative (C) | 2015-10-07 | 2015-10-16 | BENDAMUSTINE + RITUXIMAB | 99 | N | 220035241 | FLUDARABINE |
| 220018043 | 220009331 | null | 67.5 | Curative (C) | 2015-09-26 | 2015-09-29 | VINCRISTINE | N | Y | 220035243 | MELPHALAN |
| 220018044 | 220014953 | -1 | null | Disease modification (D) | null | 2016-09-14 | ALL UKALL60+ TRIAL | N | null | 220035271 | LENALIDOMIDE |
| 220018045 | 220009336 | null | null | Palliative (P) | 2014-02-28 | 2014-03-04 | Carboplatin + Cetux + FU (>Cycle 2) | N | N | 220035279 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |